首页 › 基金 › Remedium Capital Partners, LLC › SYRE
Remedium Capital Partners, LLC 对 SYRE 的持仓历史
SPYRE THERAPEUTICS INC · 医疗保健
Remedium Capital Partners, LLC 在 Q3 2026 的 13F 申报中披露持有 SYRE(SPYRE THERAPEUTICS INC)1,160,620 股,市值约 US$103.3M,约占其申报组合的 37.77%,在其申报持仓中市值排名第 1 位。 Remedium Capital Partners, LLC 最近 4 个申报季度中有 4 个季度披露了 SYRE 持仓,最早可追溯至 Q4 2025。
最后更新: 2026-11-13 · 来源: SEC EDGAR Form 13F-HR
Remedium Capital Partners, LLC 对 SYRE 的持仓演变
Remedium Capital Partners, LLC 于 Q4 2025 首次披露 SYRE 持仓:1,456,231 股(约 US$47.7M)。 该持仓在 Q2 2026 达到峰值 1,464,169 股,市值约 US$130.0M。 在 4 次申报中,Remedium Capital Partners, LLC 1 次增持、1 次减持、1 次保持不变。 最近一期申报(Q3 2026)显示持股 1,160,620 股、市值约 US$103.3M,环比减持 -303,549 股。。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2025 | 1.46M | $47.71M | 新进 |
| Q1 2026 | 1.46M | $73.45M | 持有 |
| Q2 2026 | 1.46M | $129.99M | 增持 |
| Q3 2026 | 1.16M | $103.33M | 减持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 SYRE 与 13F 数据
SYRE(SPYRE THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 66 只申报持有 SYRE,申报仓位最大的包括:PERCEPTIVE ADVISORS LLC (US$383.5M), RTW INVESTMENTS, LP (US$377.5M), Paradigm Biocapital Advisors LP (US$341.0M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 SYRE 的基金
- PERCEPTIVE ADVISORS LLC 4.32M 股 · $383.48M · Q2 2026
- RTW INVESTMENTS, LP 4.25M 股 · $377.49M · Q2 2026
- Paradigm Biocapital Advisors LP 3.84M 股 · $340.98M · Q2 2026
- Venrock Adviser, LLC 2.99M 股 · $265.05M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 2.80M 股 · $248.51M · Q2 2026
- TCG Crossover Management, LLC 1.90M 股 · $168.73M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 1.89M 股 · $167.99M · Q2 2026
- Affinity Asset Advisors, LLC 1.28M 股 · $113.56M · Q2 2026
- BRAIDWELL LP 879.47K 股 · $78.08M · Q2 2026
- Siren, L.L.C. 868.60K 股 · $77.33M · Q3 2026
- Commodore Capital LP 846.79K 股 · $75.18M · Q2 2026
- EMERALD ADVISERS, LLC 571.05K 股 · $50.84M · Q3 2026
更多关于 Remedium Capital Partners, LLC
常见问题
How long has Remedium Capital Partners, LLC held SYRE?
Remedium Capital Partners, LLC has disclosed SYRE holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Remedium Capital Partners, LLC's current position in SYRE?
As of Q3 2026, Remedium Capital Partners, LLC holds 1.16M shares of SYRE (SPYRE THERAPEUTICS INC), valued at $103.33M, representing 37.77% of its reported portfolio and ranking #1.
Has Remedium Capital Partners, LLC been buying or selling SYRE?
In the latest 13F filing (Q3 2026), Remedium Capital Partners, LLC reduced its position in SYRE. The position peaked in Q2 2026 at 1.46M shares.
Which other funds hold SYRE?
Other major institutional holders of SYRE include PERCEPTIVE ADVISORS LLC, RTW INVESTMENTS, LP, Paradigm Biocapital Advisors LP, among 66 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.